Business context and reporting period
The supplied filing is Foresight Acquisition Corp.’s unaudited Form 10-Q for the quarter ended September 30, 2021—not a 10-Q filed by P3 Health Partners Inc. It describes Foresight, a blank-check company, and its proposed business combination with P3 Health Group Holdings, LLC. Foresight had not begun operating activities or generating revenue.
Key financial metrics
| Metric | Reported amount |
|---|---|
| Q3 2021 net income | $4.85 million, including a $5.52 million noncash gain from the change in fair value of warrant liabilities |
| Nine-month 2021 net loss | $854,214 |
| General and administrative expenses | $669,547 for Q3; $1.79 million for nine months |
| Revenue and margins | No operating revenue; margins are not meaningful for this pre-combination SPAC |
| Cash and cash equivalents | $97,290 at September 30, 2021 |
| Trust Account | $316.26 million at September 30, 2021, principally for a business combination or shareholder redemptions |
| Working capital | $267,654, excluding $150,000 of franchise taxes payable |
| Operating cash flow | $1.44 million used in the first nine months of 2021 |
| Debt and liabilities | No long-term debt reported; $390,352 in current liabilities and $10.22 million in warrant liabilities |
There was no Q3 2020 operating comparison because Foresight was incorporated in August 2020 and had no activity in the corresponding inception-period presentation.
Changes versus prior periods
- Q3 shifted to net income from losses earlier in 2021, principally because warrant fair value changes produced a gain; results therefore do not reflect operating performance.
- Foresight revised previously issued 2021 financial statements to classify all public Class A shares subject to possible redemption as temporary equity. Management said the revision did not affect total assets, total liabilities, cash flows, or net income or loss, but changed equity presentation and earnings-per-share allocation.
- At September 30, the Trust Account held $316.26 million, compared with no Trust Account balance at December 31, 2020, following the February 2021 IPO.
Transaction, outlook, risks, and unusual items
- The proposed P3 transaction, announced May 25, 2021, contemplated $2.126 billion of aggregate merger consideration and a $208.7 million PIPE, subject to closing conditions. The filing describes a minimum $400 million cash condition after specified adjustments, redemptions, and financing. Completion was not assured.
- Foresight said it expected available resources to meet needs through a business combination or its deadline, but the filing gives inconsistent deadline references: February 21, 2023 in one passage and February 12, 2023 elsewhere.
- The Sponsor had committed working-capital loans, none outstanding at quarter-end. The notes describe a $300,000 commitment and an additional $600,000 commitment made October 27, 2021; MD&A instead refers to a $200,000 funding commitment as of September 30. The amounts and timing warrant reconciliation.
- Disclosure controls were deemed ineffective due to a material weakness in accounting for complex financial instruments. Management was developing remediation steps and cautioned that it could not assure they would be effective.
- Management said COVID-19 could negatively affect the company’s financial position, operations, or search for a target, but the impact was not determinable. No legal proceedings were reported.
- Warrant fair values rely in part on valuation assumptions; changes flow through earnings. Public warrants may expire worthless if no business combination is completed.
Important facts for investors to verify
- Confirm the intended issuer: this is Foresight Acquisition Corp.’s filing, not P3 Health Partners Inc.’s operating-company 10-Q.
- Check the status and final terms of the proposed P3 combination, PIPE funding, cash condition, shareholder redemptions, and required approvals.
- Reconcile the Sponsor loan commitment disclosures and the two stated business-combination deadlines.
- Review the restatement and material weakness disclosures, remediation progress, and any subsequent control deficiencies.
- Distinguish reported earnings from operating results: Q3 income was driven mainly by a noncash warrant revaluation, and Foresight reported no operating revenue.